inhibitor

Prolastin, Alpha1-Proteinase Inhibitor (Human), is indicated for chronic augmentation and maintenance therapy of individuals having congenital deficiency of alpha1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema.

First Liquid Ready-to-Use Alpha1-Proteinase Inhibitor Will Expand Treatment Options for Specialists Treating AAT Deficiency Patients

24 August 2010 - US Baxter International Inc (NYSE: BAX) said today it has inked a definitive agreement with Israeli Kamada Ltd (TLV: KMDA) for exclusive commercial rights to GLASSIA (Alpha 1-Proteinase Inhibitor (Human)), a liquid alpha1-proteinase inhibitor, in the US, Australia, New Zealand and Canada.

Glassia is a unique, high purity, ready-to-use liquid alpha- 1 proteinase inhibitor that is indicated for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor, also known as alpha-1 antitrypsin deficiency (AATD).

for exclusive commercial rights to GLASSIA[TM] [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid alpha1-proteinase inhibitor, in the United States, Australia, New Zealand and Canada.

Glassia(TM) is a unique, high purity, liquid, ready-to-use liquid Alpha- 1-Proteinase Inhibitor that is indicated for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor, also known as Alpha1-Antitrypsin Deficiency.